所有文献均来自国外最新顶级医学期刊每日更新,仅供学术研究参考
← 返回列表
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study.
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study.
👥 作者
Sunderland Nicholas (MRC Integrative Epidemiology Unit)
Asselin Geraldine (Bristol Medical School)
Henry Albert (University of Bristol)
Nelson Christopher P (Bristol)
Lemieux Perreault Louis-Philippe (United Kingdom; NIHR Bristol Biomedical Research Centre)
Asselbergs Folkert W (University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol)
Boersma Eric (Bristol)
Cappola Thomas P (United Kingdom.; Montreal Heart Institute)
Chazara Olympe (Pharmacogenomics Centre)
Chutkow William (Montréal)
Cyr Marie-Christyne (Québec)
Gkatzionis Apostolos (Canada.; Institute of Cardiovascular Science)
Gui Hongsheng (University College London)
Haefliger Carolina (London)
Hedman Åsa K (United Kingdom.; Department of Cardiovascular Sciences)
Hillege Hans (University of Leicester)
Hyde Craig L (Leicester)
Kamanu Frederick K (United Kingdom; NIHR Leicester Biomedical Research Centre)
Kardys Isabella (Glenfield Hospital)
Koekemoer Andrea L (Leicester)
Kraus William E (United Kingdom.; Montreal Heart Institute)
Lang Chim C (Pharmacogenomics Centre)
Malarstig Anders (Montréal)
Margulies Kenneth B (Québec)
Marston Nicholas A (Canada.; Department of Cardiology)
Melloni Giorgio E M (Amsterdam Cardiovascular Sciences)
Morley Michael P (Amsterdam University Medical Center)
O'Donoghue Michelle L (University of Amsterdam)
Owens Anjali T (Amsterdam)
Paul Dirk S (the Netherlands; The National Institute for Health and Care Research University College London Biomedical Research Centre)
Tilling Kate (University College London)
van der Harst Pim (London)
van Setten Jessica (United Kingdom; Institute of Health Informatics)
van Vugt Marion (University College London)
Verweij Niek (London)
Veluchamy Abirami (United Kingdom.; Department of Cardiology)
Wallentin Lars (Cardiovascular Institute)
Wang Xiaosong (Erasmus MC)
Xing Heming (University Medical Center)
Yang Yifan (Rotterdam)
White Harvey D (the Netherlands.; Penn Cardiovascular Institute)
Zannad Faiez (Perelman School of Medicine)
Smith J Gustav (University of Pennsylvania)
Brunner-La Rocca Hans-Peter (Philadelphia)
Lanfear David E (Pennsylvania)
Mann Douglas L (USA.; Centre for Genomics Research)
de Denus Simon (Discovery Sciences)
Tardif Jean-Claude (BioPharmaceuticals R&D)
Voors Adriaan A (AstraZeneca)
Samani Nilesh J (Cambridge)
Ellinor Patrick T (United Kingdom.; Novartis Institutes for Biomedical Research)
Ruff Christian T (Cambridge)
Sabatine Marc S (Massachusetts)
Sattar Naveed (USA.; Montreal Heart Institute)
McMurray John J V (Pharmacogenomics Centre)
Paternoster Lavinia (Montréal)
Dubé Marie-Pierre (Québec)
Lumbers R Thomas (Canada.; MRC Integrative Epidemiology Unit)
📋 发表信息
📖 J Am Coll Cardiol
📅 2026-01-01
🧬 PMID: 42017882
📂 分类:心衰
📝 摘要
Excess adiposity, most commonly indexed through body mass index (BMI), is strongly associated with the development of heart failure (HF). Weight loss therapies improve outcomes in patients with obesity and HF with preserved left ventricular ejection fraction (LVEF), but their effects in HF with reduced LVEF remain unclear. The aim of this work is to determine whether higher BMI is associated with adverse clinical outcomes in patients with HF and whether there is effect modification by LVEF subgroup. Two-sample Mendelian randomization (MR) was used, with genome-wide significant loci associated with BMI as instrumental variables and outcome data from a genome-wide association study (GWAS) of time-to-event clinical outcomes in patients with HF. A total of 50,636 individuals of European ancestry with established HF from 22 cohorts were included in the genetic analysis: 12 HF trials, 1 prospective case-cohort study, 9 cohorts nested within non-HF cardiovascular trials, and 1 population-based cohort derived from the UK Biobank. The exposure was genetically predicted BMI and the outcome measures were all-cause mortality and a composite of cardiovascular mortality or HF hospitalization. Genetic associations for the outcomes were derived from our GWAS and MR was used to estimate the unbiased association of genetically predicted BMI with these clinical outcomes. The mean BMI was 29.2 ± 5.8 kg/m2. Over a median follow-up of 27.0 months, all-cause mortality occurred in 11,454 patients (23%), and 11,360 participants (22%) experienced the composite endpoint. Genetically predicted BMI was associated with an increased rate of both all-cause mortality (HR per SD [4.8 BMI units] 1.21; 95% CI: 1.13-1.29; P = 9 × 10-8) and the composite outcome (HR 1.29; 95% CI: 1.20-1.38; P = 8 × 10-13). Associations were consistent across LVEF ≤40% and >40%: for all-cause mortality, HR: 1.16 (95% CI: 0.99-1.37) and 1.20 (95% CI: 0.94-1.53); and for the composite outcome, HR: 1.30 (95% CI: 1.15-1.48) and 1.57 (95% CI: 1.29-1.91), respectively. Among patients with HF, higher BMI was associated with increased all-cause mortality and cardiovascular death or HF hospitalization, supporting the potential role of weight-management strategies across the ejection fraction spectrum.
← 返回列表